Sino Biopharmaceutical Ltd
HKEX:1177

Watchlist Manager
Sino Biopharmaceutical Ltd Logo
Sino Biopharmaceutical Ltd
HKEX:1177
Watchlist
Price: 3.22 HKD 0.31% Market Closed
Market Cap: 60.5B HKD
Have any thoughts about
Sino Biopharmaceutical Ltd?
Write Note

Sino Biopharmaceutical Ltd
Tax Provision

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sino Biopharmaceutical Ltd
Tax Provision Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Tax Provision CAGR 3Y CAGR 5Y CAGR 10Y
Sino Biopharmaceutical Ltd
HKEX:1177
Tax Provision
-ÂĄ886.6m
CAGR 3-Years
16%
CAGR 5-Years
-4%
CAGR 10-Years
-10%
G
Grand Pharmaceutical Group Ltd
HKEX:512
Tax Provision
-HK$424m
CAGR 3-Years
-9%
CAGR 5-Years
-16%
CAGR 10-Years
-28%
U
United Laboratories International Holdings Ltd
HKEX:3933
Tax Provision
-ÂĄ726.1m
CAGR 3-Years
-67%
CAGR 5-Years
-51%
CAGR 10-Years
0%
C
China Traditional Chinese Medicine Holdings Co Ltd
HKEX:570
Tax Provision
ÂĄ176.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Tax Provision
-HK$3.6B
CAGR 3-Years
-22%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
H
HUTCHMED (China) Ltd
HKEX:13
Tax Provision
-$4.7m
CAGR 3-Years
0%
CAGR 5-Years
-4%
CAGR 10-Years
-14%
No Stocks Found

Sino Biopharmaceutical Ltd
Glance View

Market Cap
59B HKD
Industry
Pharmaceuticals

Sino Biopharmaceutical Ltd. emerged as a key player in the Chinese healthcare landscape, rooted in the rich cultural hubs of Beijing and Hong Kong. As the tapestry of modern medicine interweaves ever more tightly with advanced research, Sino Biopharmaceutical positions itself at this critical juncture. The company delves extensively into the discovery, development, manufacturing, and commercialization of a broad spectrum of pharmaceuticals. With a keen focus on therapeutic areas like oncology, hepatitis, and cardio-cerebral diseases, they forge pathways for innovative treatments that resonate widely in the fast-developing Chinese medical market. Driven by its Research and Development prowess, Sino Biopharmaceutical garners considerable strength from its portfolio of proprietary drugs, underscoring a growth strategy deeply rooted in innovation and quality. The financial blueprint of Sino Biopharmaceutical delicately balances its expansive production capacities with a robust distribution network, encapsulating an effective end-to-end operation from lab to patient. Revenue streams are predominantly anchored in its extensive sales of prescription drugs, particularly high-margin specialty pharmaceuticals that address critical and chronic health conditions. Leveraging strategic alliances and collaborations with both domestic and international partners, the company enhances its technological capabilities and global reach. Moreover, its enduring commitment to sustainable practices and compliance wields influence over its operational efficiencies, allowing Sino Biopharmaceutical to navigate and capitalize on regulatory environments while meeting the burgeoning healthcare needs across its business region.

Intrinsic Value
3.97 HKD
Undervaluation 19%
Intrinsic Value
Price

See Also

What is Sino Biopharmaceutical Ltd's Tax Provision?
Tax Provision
-886.6m CNY

Based on the financial report for Jun 30, 2024, Sino Biopharmaceutical Ltd's Tax Provision amounts to -886.6m CNY.

What is Sino Biopharmaceutical Ltd's Tax Provision growth rate?
Tax Provision CAGR 10Y
-10%

Over the last year, the Tax Provision growth was -42%. The average annual Tax Provision growth rates for Sino Biopharmaceutical Ltd have been 16% over the past three years , -4% over the past five years , and -10% over the past ten years .

Back to Top